Form 4 for EW Edwards Lifesciences
Accepted 2023-05-09 00:00:00 ET · period of report 2023-05-07 · accession 0001225208-23-005619 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-05-09 | 2023-05-07+ | EW | Chopra Daveen | CVP, TMTT | F - Tax | $88.74 | -2,789 | 19.9K | -12% | -$247.5K |
| D | 2023-05-09 | 2023-05-07 | EW | Chopra Daveen | CVP, TMTT | M - OptEx | $0.00 | +3,413 | 21.8K | +19% | $0 |
| D | 2023-05-09 | 2023-05-07 | EW | Chopra Daveen | CVP, TMTT | M - OptEx | $0.00 | -3,413 | 937 | -78% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-08 | F | D | 967 | $88.74 | 18,975 | D | — | — | |
| 2 | Common | Common Stock | 2023-05-07 | F | D | 1,822 | $88.74 | 19,942 | D | — | — | |
| 3 | Common | Common Stock | 2023-05-07 | M | A | 3,413 | $0.00 | 21,764 | D | — | — | (F1) On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. |
| 4 | Derivative | Performance Rights | 2023-05-07 | M | D | 3,413 | $0.00 | 937 | D | — · 2023-05-07 to 2027-05-06 | 3,413 Common Stock | (F1) On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4. |